NCT02891551View on ClinicalTrials.gov

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands

CompletedOBSERVATIONAL
Enrollment

209

Participants

Timeline

Start Date

May 1, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

December 30, 2018

Conditions
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02891551 - An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands | Biotech Hunter | Biotech Hunter